Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally
November 14, 2019
-
REGULATORY Keytruda to Get 17.5% Price Cut in February
November 13, 2019
-
REGULATORY Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
-
REGULATORY Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
-
REGULATORY Opposition Party Set to Compile HPV Vaccine Proposal by Year-End
November 8, 2019
-
BUSINESS As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
-
BUSINESS 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
-
REGULATORY MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy
November 5, 2019
-
BUSINESS Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
November 1, 2019
-
BUSINESS Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
-
BUSINESS Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
-
REGULATORY CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
-
BUSINESS AbbVie Embarking on Work Style Reform for Sales Reps, Lets Staffers Pick Locations
October 28, 2019
-
BUSINESS Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
-
REGULATORY Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
-
BUSINESS Zolgensma’s Japan Launch Delayed into 2020 as Sakigake Review Drags On, MHLW Still Eager to Make Decision by Year-End
October 23, 2019
-
BUSINESS In Shocking U-Turn, Biogen/Eisai Say to File Aducanumab in Early Next Year
October 23, 2019
-
BUSINESS JAK Debuts Draw Near in Japan Atopic Dermatitis Market, 1st Likely to Get Listing Next Spring
October 21, 2019
-
ACADEMIA Nephrology Society Poised to Compile Drug Development Guidelines for Early-Stage Kidney Disease
October 18, 2019
-
BUSINESS FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…